Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Opus Genetics Q3 2026 Results: Net Loss of $46.5M, Loss Widens

Opus Genetics reported a significant increase in net loss to $120.1 million for the nine months ended September 30, 2026, primarily driven by a $72.8 million fair value change in financial instruments. Despite the loss, the company strengthened its balance sheet through $82.9 million in financing activities, including a note purchase agreement and Series B preferred stock issuance, ending the period with $89.0 million in cash and cash equivalents.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue1.13.1
Profit before tax-46.5-17.5
Net income-46.5-17.5
EPS (diluted, $ a share)$-0.46$-0.25

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-63.1%
Source

10-Q filed with the SEC, NASDAQ: IRD. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Opus Genetics, Inc.: key numbers

Share price
$4.04Close, Nov 16
Market cap
$390M
Shares outstanding
96.65MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Opus Genetics, Inc.

All →
7:02 AM ET 8-K
Financial Results

Opus Genetics Financial Results

Opus Genetics reported financial results for the third quarter of 2026, highlighting a cash runway extending into 2029. The company achieved several clinical milestones, including full enrollment of its OPGx-LCA5 Phase 3 trial and FDA clearance of the IND for OPGx-RDH12. Additionally, the FDA approval of RYZUMVI for presbyopia triggered a regulatory milestone payment to the company.

Term
Q3 2026

“The last several months have marked a period of tremendous advancement for our leading gene therapy programs. Positive Cohort 1 data from our Phase 1/2 trial of OPGx-BEST1 provide important evidence of its potential to improve both visual function and retinal structure in patients with BEST1-related retinal disease.”

George Magrath, M.D., Chief Executive Officer of Opus Genetics

“The FDA approval of phentolamine ophthalmic solution 0.75% for presbyopia marks the second FDA-approved indication for RYZUMVI®, demonstrating the capabilities of our clinical and regulatory teams. With our cash runway into 2029, we remain focused on bringing potentially transformative gene therapies to patients with rare inherited retinal diseases.”

George Magrath, M.D., Chief Executive Officer of Opus Genetics
4:04 PM ET Form 4
Insider Selling

Opus Genetics CEO George Magrath Sells $110K of Stock

George Magrath, CEO, sold 28,258 shares of Opus Genetics, Inc. at $3.90 a share, worth $110K in total on Nov 3, 2026. Shares held after the trade: 2,010,636 (-1.4%).

Value
$110K
Shares
28,258
Price
$3.90
Role
CEO
Holding change
-1.4%
Trade date
Nov 3, 2026
4:48 PM ET Form 4
Insider Selling

Opus Genetics COO Joseph K. Schachle Sells $17K of Stock

Joseph K. Schachle, COO, sold 4,767 shares of Opus Genetics, Inc. at $3.56 a share, worth $17K in total on Oct 23, 2026. Shares held after the trade: 286,673 (-1.6%).

Value
$17K
Shares
4,767
Price
$3.56
Role
COO
Holding change
-1.6%
Trade date
Oct 23, 2026
4:41 PM ET Form 4
Insider Selling

Opus Genetics President Benjamin R. Yerxa Sells $117K of Stock

Benjamin R. Yerxa, President, sold 33,189 shares of Opus Genetics, Inc. at $3.53 to $3.55 a share (average $3.54) in 2 transactions, worth $117K in total on Oct 23, 2026. Shares held after the trade: 670,917 (-3.7%).

Value
$117K
Shares
33,189
Average price
$3.54
Role
President
Holding change
-3.7%
Trade date
Oct 23, 2026
4:29 PM ET Form 4
Insider Selling

Opus Genetics CFO Robert E. Gagnon Sells $49.6K of Stock

Robert E. Gagnon, CFO, sold 14,000 shares of Opus Genetics, Inc. at $3.55 a share, worth $49.6K in total on Oct 23, 2026. Shares held after the trade: 542,375 (-2.5%).

Value
$49.6K
Shares
14,000
Price
$3.55
Role
CFO
Holding change
-2.5%
Trade date
Oct 23, 2026
4:20 PM ET Form 4
Insider Selling

Opus Genetics CEO George Magrath Sells $34.4K of Stock

George Magrath, CEO, sold 9,591 shares of Opus Genetics, Inc. at $3.58 a share, worth $34.4K in total on Oct 23, 2026. Shares held after the trade: 2,038,894 (-0.5%).

Value
$34.4K
Shares
9,591
Price
$3.58
Role
CEO
Holding change
-0.5%
Trade date
Oct 23, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.